SCRN2抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse small intestines tissue lysate, Primary antibody: P09912(SCRN2 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P09912(SCRN2 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09912(SCRN2 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The SCRN2 antibody targets Secernin-2 (SCRN2), a protein belonging to the Secernin family, which includes SCRN1 and SCRN3. SCRN2 is implicated in regulating secretory pathways, particularly in vesicle trafficking and membrane dynamics. It is expressed in various tissues, with notable roles in neuronal and immune cells. Structurally, SCRN2 contains a conserved secernin domain, though its precise molecular mechanisms remain under investigation. Research suggests SCRN2 may interact with components of the exocytic machinery, influencing processes like cytokine secretion or synaptic transmission.

Antibodies against SCRN2 are primarily used as research tools to study its expression, localization, and function in cellular models. They enable detection via techniques like Western blotting, immunofluorescence, and immunohistochemistry. SCRN2 has garnered interest in disease contexts, including cancer and neurodegenerative disorders, where dysregulated secretion pathways contribute to pathology. For instance, altered SCRN2 levels have been observed in glioblastoma and colorectal cancer, hinting at potential roles in tumor progression or metastasis. However, its clinical relevance remains exploratory, necessitating further validation. Commercial SCRN2 antibodies are typically developed in hosts like rabbits or mice, with validation data emphasizing specificity through knockdown/knockout controls. Ongoing studies aim to clarify SCRN2's interplay with cellular signaling networks and its utility as a biomarker or therapeutic target.